Confocal Laser Microendoscopy (CellTouch) for the Diagnosis of Early Gastric Cancer: A Multicenter Clinical Study

Sponsor
Changhai Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06152783
Collaborator
Wuxi Hisky Medical Technology Co Ltd (Industry)
578
1
12
48.1

Study Details

Study Description

Brief Summary

This study is A prospective, randomized, multicenter clinical trial: The study intends to include subjects suspected of early gastric cancer, including 378 subjects with neoplastic lesions and 200 subjects with non-neoplastic lesions. The subjects are divided into two groups by random envelopes, A and B, and the endoscopic diagnosis in different groups is performed in different order (including: White light endoscopy,CellTouch, Magnifying endoscopy with NBI(ME-NBI)). Finally, the gold standard of histopathology was used to evaluate the diagnostic performance of CellTouch in the diagnosis of early gastric cancer.The study hypothesized that the sensitivity and specificity of CellTouch in the diagnosis of early gastric cancer could reach more than 90% and more than 95%.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Objectives:
    1. Histopathology was used as the gold standard to evaluate the diagnostic performance of CellTouch in the diagnosis of early gastric cancer.

    Secondary Objectives

    1. Using histopathology as the gold standard, the diagnostic performance of CellTouch and ME-NBI in the diagnosis of early gastric cancer was compared and analyzed.

    2. Histopathology was used as the gold standard to evaluate the diagnostic performance of CellTouch combined with ME-NBI and ME-NBI alone in the diagnosis of early gastric cancer.

    3. Histopathology was used as the gold standard to evaluate the diagnostic performance of CellTouch and ME-NBI in the differential diagnosis of low-grade intraepithelial neoplasia and high-grade intraepithelial neoplasia.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    578 participants
    Observational Model:
    Case-Crossover
    Time Perspective:
    Prospective
    Official Title:
    Confocal Laser Microendoscopy (CellTouch) for the Diagnosis of Early Gastric Cancer: A Multicenter Clinical Study
    Anticipated Study Start Date :
    Nov 21, 2023
    Anticipated Primary Completion Date :
    Nov 21, 2024
    Anticipated Study Completion Date :
    Nov 21, 2024

    Arms and Interventions

    Arm Intervention/Treatment
    A group

    The sequence of endoscopy in group A was as follows: white light endoscopy, ME-NBI endoscopy,Confocal laser endomicroscopy.

    B group

    The sequence of endoscopy in group B was as follows: white light endoscopy, Confocal laser endomicroscopy, ME-NBI endoscopy.

    Outcome Measures

    Primary Outcome Measures

    1. Histopathology was used as the diagnostic gold standard to evaluate the diagnostic performance of CellTouch in the diagnosis of early gastric cancer. [30 min]

      The diagnostic properties of CellTouch include: sensitivity and specificity.

    Secondary Outcome Measures

    1. Using histopathology as the diagnostic gold standard, the diagnostic performance of CellTouch and ME-NBI in early gastric cancer was compared and analyzed. [30 min]

      Diagnostic performance related indexes include: accuracy, sensitivity, specificity, positive predictive value, negative predictive value.

    2. Using histopathology as the diagnostic gold standard, the diagnostic performance of CellTouch combined with ME-NBI and ME-NBI alone in early gastric cancer was compared and analyzed. [30 min]

      Diagnostic performance related indexes include: accuracy, sensitivity, specificity, positive predictive value, negative predictive value.

    3. Using histopathology as the diagnostic gold standard, the diagnostic performance of CellTouch and ME-NBI in the differential diagnosis of low-grade intraepithelial neoplasia and high-grade intraepithelial neoplasia was evaluated. [30 min]

      Diagnostic performance related indexes include: accuracy, sensitivity, specificity, positive predictive value, negative predictive value.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 70 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. Patients aged between 18 and 70 years;

    2. Patients who have recently found suspicious lesions by gastroscopy and need further intensive examination;(Suspicious lesions refer to suspected superficial neoplastic lesions visible under white light endoscopy, including elevation type, flatness type and depression type. According to the Paris classification standard);

    3. Patients who willing to provide written informed consent.

    Exclusion Criteria:
    1. Patients with absolute contraindications to gastroscopy;

    2. Patients with advanced gastric cancer;

    3. Patients who cannot undergo histopathological examination;

    4. Patients who cannot be given general anesthesia;

    5. Patients who are pregnant or lactating patients, or prepare to conceive or who are at risk of conception due to lack of effective contraception;

    6. Patients with history of drug allergies, such as anesthetics, fluorescein sodium, bowel preparation drugs, etc.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Changhai Hospital Shanghai Shanghai China 210000

    Sponsors and Collaborators

    • Changhai Hospital
    • Wuxi Hisky Medical Technology Co Ltd

    Investigators

    • Principal Investigator: zhen-dong jin, phD, Changhai Hospital shanghai

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Changhai Hospital
    ClinicalTrials.gov Identifier:
    NCT06152783
    Other Study ID Numbers:
    • CH-2306
    First Posted:
    Dec 1, 2023
    Last Update Posted:
    Dec 1, 2023
    Last Verified:
    Nov 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Dec 1, 2023